Sign inJoin waitlistJoin the waitlist

AY

Aihua Yen

Assistant Professor · Baylor College of Medicine

Credentials: · · ·

History

Baylor College of Medicine
Present

Medical Oncology
2009–2011
Internal Medicine
2006–2009
Baylor College of Medicine
2002–2006

Research

Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Review · Pharmacology & Therapeutics · 2013 · 332 citations
Role of Systemic Therapy in Localized Renal Cell Carcinoma: Where Do We Stand and Where Are We Heading?
Review · Cancers · 2025 · Last of 5 authors · 2 citations
Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis
Systematic review or meta-analysis · Seminars in Urologic Oncology · 2024 · 2 citations

DH
David Hinojosa-Gonzalez
1 paper · 1 as a resident
Deepa Raghavan
1 paper
GS
Gustavo Salgado
1 paper
JT
Jennifer Taylor
1 paper
JS
Jeremy Slawin
1 paper
Michael Coburn
1 paper
NM
Nagaishwarya Moka
1 paper
Nan Chen
1 paper · 1 as a fellow
NV
Nikhil Vojjala
1 paper · 1 as a resident
SK
Shane Kronstedt
1 paper · 1 as a resident
VG
Viktoriya Gibatova
1 paper

Clinical trials

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
Principal investigator · Completed · Phase 1
Baylor College of Medicine
2016–2025
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Site PI · Recruiting · Phase 3
Canadian Cancer Trials Group
2025–2031
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030